Labiotech.eu

News and Trends 27 Oct 2016

Boehringer enters the Biosimilar War against Blockbuster Humira

Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […]

October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 27 Oct 2016

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress by Novartis’s CAR-T therapy program, the company is reportedly disbanding the cell and gene therapy […]

October 27, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 27 Oct 2016

Oxitec scales up Mosquito production with a new Factory in Brazil

Since Brazil became the first country in the world to deploy GM mosquitos, Oxitec has opened a factory there to produce its Friendly Aedes aegypti. Oxitec has opened a large-scale mosquito factory in Piracicaba, Brazil, to scale up production of their Friendly Aedes aegypti mosquitos. These mosquitos are effectively sterilized so they don’t transmit infectious […]

October 27, 2016 - 2 minutesmins - By Evelyn Warner

guitar singing music song Rawpixel.com fi

News and Trends 26 Oct 2016

Proteins can now Sing about their Anomalies to help cure Diseases

Researchers are generating melodies from proteins’ structures. It could be used to understand protein folding and anomalies that contribute to disease. Protein folding is an infamously difficult phenomenon to understand and predict from sequence data. A collaboration between a resident composer at the University of Tempere in Finland and a scientist at the Francis Crick […]

October 26, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 26 Oct 2016

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […]

October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

cells pipetting well plate cells Andrii Slonchak fi

News and Trends 26 Oct 2016

Biosimilars are all the rage, but how do they compare to Generics?

Biosimilars could be the future of the pharmaceutical industry, as the market could grow 10-fold in the next 5 years. But how do they differ from generic drugs? During the past decade, Europe saw the emergence of a new type of drug: biosimilars. The concept of a “similar biological medicinal product” was adopted in EU […]

October 26, 2016 - 5 minutesmins - By External Contributor

News and Trends 25 Oct 2016

The First Peanut Allergy Therapy might soon hit the Shelves

DBV Technologies announced outstanding Phase IIb results for Viaskin Peanut, which could be the first-ever commercial peanut allergy therapy in the near future. However, competition is stiff. DBV Technologies, the first French Biotech to enter the NASDAQ, aims to be the first to attain approval for a food allergy therapy. The company’s lead pipeline candidate […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 10 25 at 3.57.12 PM e1477403929643

News and Trends 25 Oct 2016

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Curetis is drastically reducing the time required to test for severe infectious diseases. The newest incorporation is expected early next year and could soon substitute the hospital standards. Curetis is a German biotech that commercializes diagnostic technologies for infectious diseases. After a very successful IPO last year, the company is advancing its Unyvero platform for fast diagnostics. The […]

October 25, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Oct 2016

Meet the Cyborg Bacteria that Culture Themselves

What if you could program your bacteria to grow in any pattern you fancy? Researchers from ETH Zurich can, and this is huge news for the Biotech Industry! Scientists from ETH Zurich have developed a fully automated system that can precisely control bacterial growth using light. What’s more, unlike other prototypes, this system can adjust to any […]

October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

crystal ball forecasting wavebreakmedia fi

7 Considerations for Commercializing a New Drug

So you have exciting science, but do you know if it will be a commercial success? Ask the drug development and commercialization experts, who have turned the pharma analytics and consultancy industry on its head! We sat down with Mirador Analytics, to talk about bringing a drug from the clinic to the market. They are […]

October 25, 2016 - 6 minutesmins - By External Contributor

News and Trends 24 Oct 2016

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

Ascendis aims to raise €103M ($112M) for Phase III trials in Growth Hormone Deficiency (GHD) that offer children a weekly alternative to daily injections. After its IPO on NASDAQ last year, the Danish Ascendis is making an underwritten public offering in the US that aims to raise €103M ($112M) to advance its TransCon pipeline. The funds will be directed to […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Boehringer enters the Biosimilar War against Blockbuster Humira

UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle

Oxitec scales up Mosquito production with a new Factory in Brazil

Proteins can now Sing about their Anomalies to help cure Diseases

Can this new Antibody-Drug Conjugate Collaboration make it to the Top?

Biosimilars are all the rage, but how do they compare to Generics?

The First Peanut Allergy Therapy might soon hit the Shelves

This Diagnostic Tool beats the Standard for Respiratory Infection Tests

Meet the Cyborg Bacteria that Culture Themselves

7 Considerations for Commercializing a New Drug

A €103M Target to Reduce Drug Dosage with a Slow-Release Tech

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!